Form 4/A for ABBV AbbVie
Accepted 2025-02-07 00:00:00 ET · period of report 2024-02-15 · accession 0001415889-25-003337 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMA | 2025-02-07 | 2024-02-15 | ABBV | Thakkar Roopal | EVP, CSO, R, D | A - Grant | $0.00 | +11.1K | 41.3K | +37% | $0 |
| DA | 2025-02-07 | 2024-02-15 | ABBV | Thakkar Roopal | EVP, CSO, R, D | A - Grant | $0.00 | +13.9K | 13.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.01 par value | 2024-02-15 | A | A | 5,900 | $0.00 | 36,125 | D | — | — | (F1) Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| 2 | Common | Common Stock, $0.01 par value | 2024-02-15 | A | A | 1,572 | $0.00 | 37,697 | D | — | — | (F2) Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| 3 | Common | Common Stock, $0.01 par value | 2024-02-15 | A | A | 1,476 | $0.00 | 39,173 | D | — | — | (F3) Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| 4 | Common | Common Stock, $0.01 par value | 2024-02-15 | A | A | 2,140 | $0.00 | 41,313 | D | — | — | (F4) Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| 5 | Derivative | Option (Right to buy) | 2024-02-15 | A | A | 13,868 | $0.00 | 13,868 | D | $175.28 · 2025-02-15 to 2034-02-14 | 13,868 Common Stock | (F5) Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,775 on February 15, 2025, 7,775 on February 15, 2026, and 7,774 on February 15, 2027. (F6) Due to an administrative error the exercise price for options awarded February 15, 2024 was previously reported as $0 but the correct value of $175.28 is reflected in this amendment. |